CELC: the balance sheet

MyFinsight

Balance Sheets	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Cash and cash equivalents	145,191	165,703	74,252	46,354
Investments	241,873	275,794	380,726	122,032
Prepaid clinical trial costs	15,374	18,896	NaN	NaN
Other current assets	6,491	5,266	20,519	14,718
Total current assets	408,929	465,659	475,497	183,104
Total property and equipment, gross	NaN	2,658	NaN	NaN
Less accumulated depreciation	NaN	2,159	NaN	NaN
Property and equipment, net	619	499	417	357
Operating lease right-of-use assets	13	51	90	131
Other non-current assets	603	349	NaN	NaN
Total assets	410,164	466,558	476,004	183,592

Accrued expenses	NaN	NaN	27,278	28,644
Accounts payable	10,454	6,407	11,418	11,158
Accrued clinical trial costs	8,771	16,826	NaN	NaN
Other accrued expenses	13,973	20,865	NaN	NaN
Operating lease liabilities, current	13	54	96	139
Total current liabilities	33,211	44,152	38,792	39,941
Convertible notes	195,566	195,324	195,083	NaN
Operating lease liabilities	NaN	NaN	NaN	0
Note payable	127,862	126,527	125,166	99,276
Total liabilities	356,639	366,003	359,041	139,217
Common stock, 0.001 par value 95,000,000 shares authorized as of march 31, 2026, and december 31, 2025 48,347,390 and 48,244,960 shares issued and outstanding as of march 31, 2026, and december 31, 2025, respectively	48	48	43	39
Additional paid-in capital	555,215	549,404	514,844	398,456
Accumulated deficit	-501,738	-448,897	-397,924	-354,120
Total stockholders equity	53,525	100,555	116,963	44,375
Total liabilities and stockholders equity	410,164	466,558	476,004	183,592

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.